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Pulmonary complications
in 110 consecutive renal
transplant recipients
C. L. Edelstein, J. C. Jacobs, M. R. Moosa
The pulmonary complications in 110 consecutive renal
transplant recipients OR cyclosporin and low-dose steroid
immunosuppression were studied retrospectively. The
pulmonary complications were: acute pulmonary oedema
in 19 patients, pneumonia in 18, tuberculosis in 9, acute
pulmonary embolism in 5, and lung abscess in 1. Sixty-
nine patients (62,7%) had no pulmonary complications;
69% of the complications occurred in the first 4 months
after the transplant. Pulmonary tuberculosis became
evident later. The mean age, period of follow-up, human
leucocyte antigen (HLA) B/OR mismatches, mean serum
urea and serum creatinine concentrations, systolic and
diastolic blood pressures, and cyclosporin dosage did not
differ between the groups with no complications,
infectious complications and non-infectious complications.
The number of rejection episodes treated with bolus
steroids was significantly higher in the infectious and non-
infectious complications groups compared with the group
with no complications.
The incidence of pulmonary complications after renal
transplantation, especially pneumonia and tuberculosis,
was still high despite the use of low-dose steroids and
cyclosporin. Pulmonary complications were the
commonest cause ofaeath in the first 3 years after the
transplant. A high index of suspicion for pulmonary
tuberculosis and pulmonary embolism in these patients is
necessary.
S AfrMed J 1995; 85: 160-163.
Patient and renal allograft survival at Tygerberg Hospital has
improved dramatically over the past decade with the use of
cyclosporin A (CyA). Ninety-four per cent of recipients are
still alive at 1 year, and graft survival is over 70% for cadaver
kidneys.'
However, renal transplantation is followed by a variety of
complications that may cause significant morbidity and
mortality. In a recent 'state of the art' review, pulmonary
complications were reported to occur in 18 - 24% and
pneumonias in 8 - 16% of renal allograft recipients.> The
studies reviewed were from the pre-CyA era. We could find
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only two major studies of pneumonias after renal
transplantation in the CyA era.3.' It is unknown whether the
incidence of pulmonary complications after renal
transplantation has changed in the CyA era, and it is
controversial whether the incidence of pneumonias has
changed.
Tuberculosis is still endemic in the Cape Town area. The
incidence of pulmonary tuberculosis after renal
transplantation in endemic areas is high.' The incidence of
pulmonary complications post-renal transplantation in a
tuberculosis-endemic area is not known.
The aims of our study were: (I) to describe the pulmonary
complications in a group of renal transplant patients on'CyA
and low-dose steroid immunosuppression; and (iJ) to analyse




One hundred and ten consecutive patients who underwent
renal transplantation between October 1988 and November
1991 were studied retrospectively in November 1992.
Follow-up information was recorded either until the patient
died, or until the immunosuppression was stopped and
dialysis was resumed.
Atelectasis or respiratory depression occurring in the first
postoperative week was regarded as an anaesthetic
complication and was not included in this study.
Patients received the following immunosuppressive
regimen: (I) methylprednisolone 500 mg intravenously
immediately pre-operatively and on day 1 postoperatively.
Methylprednisolone 250 mg intravenously was given on day
2 postoperatively and 125 mg intravenously on day 3
postoperatively; VI) oral methylprednisolone 24 mg per day,
irrespective of body mass, was started on day 2
postoperatively. At 1 month postoperatively it was tapered
by 4 mg every 2 weeks until a dose of 8 mg was reached;
(iil) azathioprine 50 mg per day, irrespective of body mass,
was started on day 2 postoperatively; (iv) CyA 10 mg/kg/day
was started immediately pre-operatively and then adjusted
to keep whole blood levels between 400 and 600 ng/ml
(fluorescent polarisation immunoassay) in the first 6 months
and between 200 and 400 ng/ml after 6 months; and
(v) rejection episodes were treated with an intravenous bolus
of methylprednisolone 500 mg followed by 250 mg on 2
further consecutive days.
All patients received prophylactic cefoxitin 1 g
intravenously immediately pre-operatively followed by 1 g
8-hourly for three doses postoperatively.
Definitions
1. Acute pulmonary oedema: (i) fluid overload on clinical
examination plus a radiological picture of pulmonary
oedema; and (if) clinical or radiological improvement with
diuretic therapy, treatment of rejection, or dialysis.
2. Acute pulmonary embolism: (I) clinical picture
compatible witt; pulmonary embolism, e.g. acute dyspnoea,
pleural rub, hypoxia; and (if) a ventilation/perfusion lung scan
highly suggestive of pulmonary emboli.
3. Pneumonia: (I) clinical signs and symptoms, e.g.
cough, sputum production, focal area of crepitations, or
I
bronchial breathing; and (if) opacity, consolidation or nodule
on chest radiology.
4. Pulmonary tuberculosis: (J) the presence in sputum,
or pleural fluid or tissue of acid-alcohol-fast bacilli; (il) the
culture of Mycobacterium tuberculosis from sputum or
pleural fluid; or (iif) the presence of caseating granuloma in
lung tissue.
Statistical analysis
Variables between the control group and the infectious and
non-infectious groups were analysed by means of the
unpaired Student's Hest.
Results
Over the 3-year period 110 patients underwent renal
transplantation. The mean period of follow-up for the whole
group was 632 days (range 1 - 1 487). No patients were lost
to follow-up.
Ninety-two per cent of the complications occurred in the
first year and of these 69% occurred in the first 4 months
post-transplant (Table I).
Table I. Pulmonary complications post-renal transplant
Mean time
No. % (days)
No complication 69 62,7
Infectious complications
Pneumonia 18 16,3 91
Lung abscess 1 0,9 90
Tuberculosis 9 8,2 297
Non-infectious complications
Acute pulmonary oedema 19 17,3 85
Pulmonary embolism 5 4,5 116
Some patients had more than one complication.
The actual 1-year graft survival rate of the whole group
was 71%. The 1-year patient survival rate was 93,7%.
. Pulmonary complications were the commonest cause of
death in the 3-year period (Table 11).
Eighteen patients (16%) developed 22 episodes of
pneumonia at a mean time of 91 days post-transplant
(Table Ill).
Pulmonary tuberculosis developed in 9 patients (8,2%) at
a mean time of 150 days post-transplant (Table IV). Two out
of the 9 patients died of pulmQjnary tuberculosis.
Table IV. Pulmonary tuberculosis post-renal transplant
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Table 11. Deaths post-renal transplant
Patient Time (days) Cause of death
1st year
1 1 Surgical
2 4 Myocardial infarct
3 43 Pulmonary embolism
4 55 Myocardial infarct
5 60 Gastro-intestinal bleeding
6 144 Pulmonary embolism




10 690 Pulmonary tuberculosis
3rd year
11 930 Bacterial septicaemia
Table Ill. Pneumonia post-renal transplant
Time Sputum Anti-
Patient (days) Lobe culture biotics Outcome
1 (H) 28 RLL p,A Cured
2 (H) 58 RLL C, Clox Cured
3 (H) 5 RLL S. aureus C Cured
(H) 21 RLL CTZ Cured
(C) 120 LLL N. meningitidis Cured
4 (H) 7 LLL CEF Cured
5 (H) 31 LLL CT)( Cured
6 (H) 30 RUL CT)( Recurred
(C) 60 Unknown S. aureus A, Cip. Cured
Clox
7 (C) 60 3 Lobe K. pneumoniae A,CEF, Cured
Clox
8 (H) 2 LLL CEF. Co Cured
9 (C) 90 RUL Cured
10 (C) 240 LUL H. influenzae C Cured
S. faecalis
(C) 660 RUL A.CEF Cured
11 (H) 7 RLL CT)( Cured
12 (H) 6 RLL CT)( Cured
13 (C) 350 RLL P aeruginosa CTZ Cured
S. pneumoniae
14 (H) 4 RLL E. coli C Prolonged
15 (C) 134 3 Lobe E. coli CEF, Cured
Clox
16 (C) 124 RML, RLL A.P Cured
17 (H) 7 Unknown S. pneumoniae C Cured
18 (H) 60 RLL C. Gen. Cured
Clox
p;; piperacillin, A = amikacin, Gen ;; gentamicin, Clox ;; cloxacillin, C ;; cefoxitin,
CTZ ;; ceftazidime. CTX = ceftriaxone, CEF ;; cefotaxime, Cip ;; ciprofloxacin,
Co =co-trimoxazole; (H) =hospitai acquired, (C) = community acquired; RLL, RML,
RUL = right lower, middle, upper lobe; LLL, LUL = left lower, upper lobe.
Patient Complication Microbiology Time (days) Outcome
Effusion Pleural biopsy: 210 Cured
(+)AFB and granulomas
Bronchopneumonia Postmortem (+)ZN 690 Died
2 Nodule (+)tuberculosis culture 270 Cured
4 Nodule ZN(-), (+)tuberculosis culture 180 Cured
5 Bronchopneumonia (+)tuberculosis culture 90 Cured
6 Miliary tuberculosis (+)bone marrow granulomas (-)ZN 120 Graft loss
7 Bronchopneumonia Post mortem (+)ZN 150 Died
8 Bronchopneumonia (+)ZN 150 Cured
9 Pleural effusion (+)ZN 90 Graft loss
ZN = Ziehl-Neeisen staining.
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Table VII. PUlmonary complications in the three groups
Table V. Acute pulmonary oedema post-renal transplant
Table VI. Acute pulmonary embolism post-renal transplant
The commonest cause of acute pulmonary oedema post-
renal transplant was acute renal allograft rejection (fable V).
Discussion
A recent 'state of the art' review of pulmonary complications
after transplantation quotes an 18 - 24% incidence of
pulmonary complications and an 8 - 16% incidence of
pneumonias after renal transplantation! The studies
reviewed were from the pre-CyA era when very high doses
of steroids were used and it is unknown whether the
incidence of pulmonary complications has changed in the
CyA, low-dose steroid era.6-9 There have only been two
studies of pulmonary infections in the CyA era.3" The
Minnesota randomised prospective trial of CyA versus
azathioprine/antilymphocyte globulin for immunosuppreS9ion
in renal allograft recipients3 found that the CyA group had
fewer pneumonia episodes than the azathioprine
antilymphocyte globulin-treated group (3,7% v. 9,2%).
However, the Canadian Multicentre Transplant Study Group'
found that pneumonia occurred equally in the CyA and
conventionally treated groups (6% in both groups). We
found pulmonary complications in ?7% of our renal .
transplant patients and pneumonias in 16,3%. AlthoUgh our
patients received CyA and low-dose steroids the incidence
of pulmonary complications is high and comparable with
studies from the pre-CyA era. The infectious and non-
infectious complications groups did not have lower monthly
incomes or higher unemployment rates than the control
group.
The high incidence of pulmonary tuberculosis in our renal
transplant patients is disturbing, although not surprising as
tuberculosis is still endemic in the Cape Town area. This
high incidence of tuberculosis was present despite the fact
that transplant patients with either a previous history of
tuberculosis or any old scarring on chest radiographs are
prescribed prophylactic isoniazid. Four out of the 9 patients
with tuberculosis either died or lost their grafts. Pulmonary
tuberculosis therefore remains an important problem in renal
transplant recipients in developing countries, especially in
endemic areas.'
Positive microbiological culture was obtained in less than
50% of the episodes of pneumonia. However, all patients
responded to the second- or third-generation cephalosporin
in combination with either an aminoglycoside or cloxacillin
or both. Bronchoscopies were not routinely done, and no
patients developed Pneumocystis carinii pneumonia, CMV
pneumonia or fungal pneumonia. However, pulmonary
tuberculosis took the form of a bronchopneumonia in 5
patients, and was first diagnosed at postmortem
examination in 2 cases.
Although the incidence of pulmonary embolism is much
reduced in uraemia, renal transplantation re-establishes the
risk.' Improved surgical technique and earlier postoperative
mobilisation have reduced the risk of pulmonary embolism
after renal transplantation. IQ Superinfection in infarcted lung
is well described," and occurred in 1 of our patients who
developed a lung abscess in an area of infarcted lung.
Pulmonary disease has been described as the most
important single cause of mortality after renal
transplantation.' This was confirmed in our stUdy in the first
3 years post-transplant. However, pulmonary tuberculosis
and pulmonary embolism as opposed to pneumonia were






























































Patient Time (days) Diagnosis Outcome
1 390 Lung scan Alive
2 60 Lung scan Alive
3 43 Postmortem Died
4 84 Lung scan Died
5 6 Lung scan Alive
Five patients developed pulmonary embolism post-renal
transplant (fable VI). One case was diagnosed only at post-
mortem, and in 2 cases it was thought to be the cause of
death.
The number of rejection episodes, treated with high-dose
bolus steroids in the first year, was significantly higher in
both the infectious and non-infectious complications groups











Mean CyA dose (mg/kg)
'P-value = 0,02.
tp-vaJue = 0,026.
Mean values::;: mean of 1st year.
SBP/DBP = syslollcldiaslollc blood pressure.
Monthly income and unemployment rates at the time of
assessment for the renal replacement programme were used
as crude objective parameters of socio-economic status.
The mean monthly income (R) and unemployment status
(% of the total patients) was R630 and 29% in the group
without pulmonary complications, R694 and 18% in the
infectious pulmonary complications group, and R703 and
0% in the non-infectious pulmonary complications group.
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cases of pulmonary tuberculosis and 1 case of pUlmonary
embolism were first diagnosed at postmortem examination,
suggesting that one should have a high index of suspicion
for these conditions post-renal transplant.
The patients with no pulmonary complications had fewer,
rejection episodes. The increased amount of bolus steroid
therapy in the infectious complications group may have
contributed to the increased incidence of pulmonary
infections in this group. Acute allograft rejection treated with
bolus steroids was the commonest cause of acute
pulmonary oedema in the non-infectious group. This may
account for the fact that the non-infectious group received
more bolus steroids than the control groups.
Conclusions
Our incidence of pulmonary complications after renal
transplantation, especially pneumonia and tuberculosis, is
still high, despite the use of low-dose steroids and CyA.
Most of these complications occurred in the first year after
the transplant. Pulmonary complications, especially
pulmonary tuberculosis and pulmonary embolism,
contributed significantly to the mortality of our renal allograft
recipients.
The authors would like to thank Professor J. R. Joubert for
reviewing the manuscript.
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100 years ago ...
... there is a matter which ... is of such first-rate
importance, that the absence of any provision from the
statute book in connection therewith should be noted. In the
matter of death certificates, namely, there is no general law
which requires the cause of death to be stated. This is
rectified as far as Johannesburg is concerned by the
Regulations of the Sanitary Board. Within the jurisdiction of
the said body no burial is allowed to take place before a
certificate is obtained from the Registrar of Deaths, and this.
certificate is not granted without the production of a
certificate stating the cause of death from some duly
qualified practitioner. (It is not stated whether qualified
means licensed, but that is the construction which should
be placed upon it).
It would be superfluous to point out that this is a very
unhealthy state of affairs, and must of necessity allow a
large number of crimes of violence to go undetected which
would otherwise be brought to light.
(A. Stockenstrom, S A Medical Journal, March 1895, p. 300).
50 years ago ...
The case under investigation showed the symptomatology
of meningitis and of an acute ascending paralysis, and at
post-mortem the appearances of the meninges suggested a
meningeal infection, as numerous greyish nodules were
present in the pia-arachnoid. Microscopic examination of the
nodules revealed that they were composed of masses of
mononuclear cells and no organisms were observed or
isolated.
The histological examination of the cord revealed changes
which were very suggestive of acute anterior poliomyelitis.
Such post-mortem and histological changes are, however,
not definitely diagnostic of this condition ...
The production of Characteristic paralysis in a Green
African monkey, Lasiopyga (Cercopithecus) aathiops sabaaus,
and the failure to produce any effect on guinea-pigs or mice,
which are susceptible to most neurotropic virus diseases of
man, pointed to the fact that we were dealing with a strain
of poliomyelitis virus. The transfer of the infection of two
South African black-face monkeys with the production of
characteristic paralysis, and the histological appearances of
the cord of all three animals, confirmed this diagnosis.
The infection produced in the South African black-face
monkeys, Lasiopyga (Cercopithecus) pygerythrus, is of
particular interest as we have been unable to find a
reference to the susceptibility of this species to poliomyelitis
virus.
(M. H. Finlayson and J. F. Wicht, S A Medical Journal,
24 March 1945, p. 101).
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